vir-5500
Generic: Anti-PSMA/CD3 Protease-activated T-cell Engager AMX-500
vir-5500: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vir Biotechnology, Inc. (VIR) | Phase 1 |
Clinical Trials (1)
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer
Frequently asked questions
Who is developing vir-5500?
vir-5500 is being developed by Vir Biotechnology, Inc..
How many clinical trials involve vir-5500?
BioSniper tracks 1 clinical trial involving vir-5500.
Get deeper analysis on vir-5500
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis